D.E. Shaw & Co’s Revance Therapeutics, Inc. RVNC Stock Holding History

D.E. Shaw & Co’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-30,000	Closed	-$91.2K	–	4875
2024 Q4	$91.2K	Hold	30,000	–	–	﹤0.01%	4173
2024 Q3	$156K	Hold	30,000	–	–	﹤0.01%	4203
2024 Q2	$77.1K	Hold	30,000	–	–	﹤0.01%	4193
2024 Q1	$148K	Hold	30,000	–	–	﹤0.01%	3963
2023 Q4	$264K	Hold	30,000	–	–	﹤0.01%	3792
2023 Q3	$344K	Buy	+30,000	New	+$577K	﹤0.01%	3566

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

D.E. Shaw & Co's RVNC Position: Q1 2025 in Review

D.E. Shaw & Co sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 1,367,343 shares — an estimated $4.16M sold.

D.E. Shaw & Co first reported a position in RVNC in Q2 2015 and held it in 31 quarters. The position peaked at $73.8M in Q1 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

D.E. Shaw & Co reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
D.E. Shaw & Co sold 1,367,343 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $4.16M.
D.E. Shaw & Co first reported a position in Revance Therapeutics, Inc. in Q2 2015 and held it in 31 quarters.
D.E. Shaw & Co's Revance Therapeutics, Inc. position peaked at $73.8M in Q1 2023.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on D.E. Shaw & Co's 13F filing for Q1 2025, filed 15 May 2025.